All FDA-approved EMA-approved PMDA-approved
Target Card Uniprot Example: P23975

exemestane 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
aromatase inhibitors	1122	107868-30-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: aromasine FCE 24304 exemestane aromasin	a hormonal antineoplastic agent Molecular weight: 296.41 Formula: C20H24O2 CLOGP: 3.28 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 34.14 ALOGS: -4.64 ROTB: 0 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Drug dosage:

Dose	Unit	Route
25	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	1 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.35 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	42 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Oct. 21, 1999	FDA	PHARMACIA AND UPJOHN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Malignant neoplasm progression	1773.67	13.90	961	43608	67163	50493392
Metastases to bone	1244.25	13.90	500	44069	17495	50543060
Metastases to liver	999.83	13.90	442	44127	19662	50540893
Neoplasm progression	798.02	13.90	426	44143	28731	50531824
Osteonecrosis of jaw	583.61	13.90	361	44208	32165	50528390
Disease progression	521.04	13.90	525	44044	95341	50465214
Metastases to lung	427.40	13.90	204	44365	10816	50549739
Stomatitis	378.50	13.90	456	44113	100888	50459667
Tumour marker increased	358.93	13.90	133	44436	3707	50556848
Breast cancer metastatic	348.34	13.90	174	44395	10190	50550365
Metastases to lymph nodes	331.48	13.90	149	44420	6875	50553680
Pneumonitis	311.13	13.90	236	44333	29274	50531281
Drug ineffective	307.84	13.90	171	44398	819162	49741393
Mucosal inflammation	234.62	13.90	229	44340	39913	50520642
Pleural effusion	232.43	13.90	321	44248	81133	50479422
Metastases to skin	190.81	13.90	64	44505	1319	50559236
PIK3CA-activated mutation	189.08	13.90	56	44513	754	50559801
Bone pain	175.18	13.90	212	44357	47017	50513538
Osteonecrosis	173.53	13.90	150	44419	22367	50538188
Breast cancer	171.41	13.90	200	44369	42690	50517865
Lymphoedema	167.89	13.90	103	44466	9019	50551536
Metastases to pleura	158.89	13.90	55	44514	1251	50559304
Breast cancer recurrent	134.05	13.90	66	44503	3742	50556813
Bone disorder	126.75	13.90	116	44453	18636	50541919
Rheumatoid arthritis	126.55	13.90	15	44554	202535	50358020
Metastases to central nervous system	125.00	13.90	93	44476	11189	50549366
Metastases to spine	123.90	13.90	57	44512	2774	50557781
Bone lesion	123.16	13.90	69	44500	5101	50555454
Ascites	115.44	13.90	150	44419	35711	50524844
Bone sequestrum	115.22	13.90	44	44525	1334	50559221
Metastases to peritoneum	114.56	13.90	54	44515	2779	50557776
Palmar-plantar erythrodysaesthesia syndrome	114.28	13.90	113	44456	19985	50540570
Second primary malignancy	111.99	13.90	72	44497	6842	50553713
Hepatic lesion	107.92	13.90	58	44511	3950	50556605
Metastasis	105.88	13.90	59	44510	4316	50556239
General physical health deterioration	102.73	13.90	317	44252	142117	50418438
Off label use	102.13	13.90	163	44406	474263	50086292
Carbohydrate antigen 15-3 increased	101.36	13.90	38	44531	1094	50559461
Neutropenia	97.30	13.90	319	44250	147646	50412909
Nail disorder	96.47	13.90	75	44494	9633	50550922
Therapeutic product effect decreased	96.00	13.90	6	44563	136044	50424511
Ejection fraction decreased	95.91	13.90	99	44470	18421	50542134
Hot flush	94.20	13.90	152	44417	44017	50516538
Exposed bone in jaw	94.02	13.90	47	44522	2753	50557802
Malignant pleural effusion	92.95	13.90	44	44525	2286	50558269
Cough	91.88	13.90	438	44131	240826	50319729
Joint swelling	87.46	13.90	54	44515	245232	50315323
Pseudocirrhosis	86.30	13.90	29	44540	601	50559954
Pleural neoplasm	84.98	13.90	23	44546	218	50560337
Interstitial lung disease	83.55	13.90	160	44409	53016	50507539
Infusion related reaction	81.63	13.90	24	44545	169533	50391022
Hormone receptor positive breast cancer	81.21	13.90	26	44543	460	50560095
Synovitis	80.30	13.90	8	44561	123857	50436698
Lymphangiosis carcinomatosa	74.91	13.90	31	44538	1165	50559390
Injection site pain	69.85	13.90	8	44561	111016	50449539
Hyperglycaemia	67.90	13.90	118	44451	36287	50524268
Lymphadenopathy mediastinal	66.66	13.90	36	44533	2475	50558080
Hypotension	66.04	13.90	66	44503	235403	50325152
Abdominal discomfort	66.04	13.90	64	44505	231577	50328978
Aphthous ulcer	64.77	13.90	62	44507	10535	50550020
Gamma-glutamyltransferase increased	63.23	13.90	102	44467	29521	50531034
Eastern Cooperative Oncology Group performance status worsened	62.94	13.90	23	44546	615	50559940
Skin toxicity	61.53	13.90	40	44529	3873	50556682
Neuropathy peripheral	59.45	13.90	204	44365	96553	50464002
Osteolysis	57.86	13.90	33	44536	2524	50558031
Polyneuropathy	57.73	13.90	62	44507	12069	50548486
Gingival swelling	57.73	13.90	38	44531	3757	50556798
Arthropathy	57.30	13.90	34	44535	157872	50402683
Tooth extraction	57.18	13.90	54	44515	9021	50551534
Glossodynia	56.26	13.90	16	44553	115553	50445002
Device related thrombosis	56.21	13.90	26	44543	1281	50559274
Treatment failure	55.29	13.90	26	44543	137611	50422944
Epistaxis	54.33	13.90	151	44418	63803	50496752
Decreased appetite	52.87	13.90	330	44239	200593	50359962
Abdominal lymphadenopathy	50.74	13.90	20	44549	661	50559894
Sinusitis	47.57	13.90	48	44521	170510	50390045
Toxicity to various agents	47.49	13.90	71	44498	212428	50348127
Overdose	46.38	13.90	15	44554	99712	50460843
Metastases to chest wall	46.30	13.90	17	44552	461	50560094
Fall	45.85	13.90	147	44422	334785	50225770
Injection site erythema	45.65	13.90	6	44563	74930	50485625
Oral pain	45.19	13.90	80	44489	24953	50535602
Discomfort	44.26	13.90	20	44549	108360	50452195
Peritoneal disorder	43.64	13.90	16	44553	432	50560123
Dysgeusia	43.57	13.90	102	44467	38814	50521741
Intentional overdose	43.35	13.90	3	44566	62501	50498054
Lung infiltration	43.05	13.90	56	44513	13337	50547218
Product dose omission issue	41.48	13.90	61	44508	183777	50376778
Oral cavity fistula	41.40	13.90	17	44552	626	50559929
Blood lactate dehydrogenase increased	41.25	13.90	67	44502	19495	50541060
Drug hypersensitivity	41.11	13.90	101	44468	250909	50309646
Weight decreased	41.06	13.90	334	44235	220911	50339644
Hepatic failure	41.03	13.90	89	44480	32194	50528361
Osteitis	40.66	13.90	28	44541	2982	50557573
Hypersensitivity	40.64	13.90	80	44489	215081	50345474
Intentional product use issue	40.62	13.90	9	44560	76909	50483646
Metastases to meninges	40.43	13.90	24	44545	1978	50558577
Therapeutic product effect incomplete	40.43	13.90	15	44554	91500	50469055
Periodontitis	40.17	13.90	28	44541	3041	50557514
Superinfection	39.84	13.90	24	44545	2032	50558523
Osteomyelitis	39.79	13.90	71	44498	22282	50538273
Fatigue	39.52	13.90	856	43713	706745	49853810
Pulmonary mass	39.35	13.90	64	44505	18641	50541914
Metastases to the mediastinum	39.27	13.90	15	44554	455	50560100
Metastases to pelvis	39.16	13.90	14	44555	351	50560204
Invasive ductal breast carcinoma	38.78	13.90	36	44533	5885	50554670
Gingival erythema	38.47	13.90	16	44553	609	50559946
Swelling	37.67	13.90	75	44494	200797	50359758
Invasive lobular breast carcinoma	37.28	13.90	16	44553	659	50559896
Metastases to soft tissue	37.08	13.90	11	44558	149	50560406
Metastases to adrenals	36.85	13.90	16	44553	678	50559877
Lymphadenopathy	36.62	13.90	87	44482	33412	50527143
Sequestrectomy	34.37	13.90	16	44553	800	50559755
Aspartate aminotransferase increased	34.36	13.90	148	44421	77850	50482705
Creutzfeldt-Jakob disease	33.74	13.90	10	44559	135	50560420
Haematotoxicity	33.50	13.90	38	44531	7857	50552698
Blood alkaline phosphatase increased	33.25	13.90	90	44479	37436	50523119
Bradycardia	33.10	13.90	8	44561	64418	50496137
Wound	32.78	13.90	27	44542	105767	50454788
Hepatic enzyme increased	32.55	13.90	44	44525	137336	50423219
Blood creatinine increased	32.40	13.90	143	44426	76017	50484538
Confusional state	31.87	13.90	73	44496	185855	50374700
Irritable bowel syndrome	31.62	13.90	4	44565	51437	50509118
Psoriatic arthropathy	30.56	13.90	3	44566	47029	50513526
Anaemia	30.42	13.90	348	44221	252108	50308447
Jaw disorder	30.35	13.90	29	44540	4914	50555641
Condition aggravated	30.03	13.90	147	44422	296911	50263644
Somnolence	29.79	13.90	57	44512	154928	50405627
Purulent discharge	29.66	13.90	27	44542	4305	50556250
Musculoskeletal stiffness	29.59	13.90	42	44527	128439	50432116
Fibrous histiocytoma	29.09	13.90	12	44557	447	50560108
Dyspnoea	28.74	13.90	657	43912	546951	50013604
C-reactive protein increased	27.65	13.90	124	44445	66350	50494205
Radiation skin injury	27.55	13.90	14	44555	849	50559706
Pericardial effusion	27.48	13.90	66	44503	25523	50535032
Blister	27.47	13.90	21	44548	85397	50475158
Breast cancer female	27.39	13.90	32	44537	6830	50553725
Multiple sclerosis relapse	27.25	13.90	3	44566	42961	50517594
Weight increased	26.62	13.90	90	44479	201801	50358754
Carcinoid tumour pulmonary	26.61	13.90	11	44558	412	50560143
Pain in jaw	26.23	13.90	84	44485	38344	50522211
Adverse drug reaction	26.21	13.90	8	44561	55214	50505341
Pathological fracture	26.07	13.90	33	44536	7649	50552906
Gingivitis	25.85	13.90	32	44537	7252	50553303
Ill-defined disorder	25.80	13.90	8	44561	54646	50505909
Metastases to thorax	25.58	13.90	9	44560	215	50560340
Tumour marker abnormal	25.39	13.90	9	44560	220	50560335
Myocardial infarction	24.86	13.90	25	44544	89002	50471553
Feeding disorder	24.65	13.90	38	44531	10575	50549980
Hospitalisation	24.10	13.90	15	44554	67922	50492633
Mouth swelling	24.09	13.90	23	44546	3893	50556662
Pancreatic neoplasm	24.08	13.90	12	44557	698	50559857
Product use issue	23.78	13.90	61	44508	149414	50411141
Hepatic atrophy	23.75	13.90	9	44560	267	50560288
Mouth ulceration	23.62	13.90	66	44503	27958	50532597
Hallucination	23.56	13.90	6	44563	46651	50513904
Debridement	23.46	13.90	14	44555	1165	50559390
Uterine mass	23.41	13.90	9	44560	278	50560277
Excessive granulation tissue	23.38	13.90	12	44557	743	50559812
Oedema peripheral	23.35	13.90	227	44342	157734	50402821
Tremor	23.20	13.90	41	44528	114862	50445693
Pulmonary tumour thrombotic microangiopathy	23.18	13.90	6	44563	47	50560508
Wrong technique in product usage process	23.04	13.90	10	44559	55500	50505055
Incorrect dose administered	23.01	13.90	7	44562	48407	50512148
Mobility decreased	22.85	13.90	22	44547	79926	50480629
Trigger finger	22.84	13.90	22	44547	3766	50556789
Loss of personal independence in daily activities	22.80	13.90	17	44552	70033	50490522
Asthenia	22.77	13.90	401	44168	318641	50241914
Nail dystrophy	22.57	13.90	12	44557	799	50559756
Mucosal dryness	22.56	13.90	18	44551	2399	50558156
Tumour marker decreased	22.06	13.90	6	44563	58	50560497
Axillary pain	22.02	13.90	15	44554	1569	50558986
Erysipelas	21.81	13.90	28	44541	6580	50553975
Medication error	21.73	13.90	3	44566	36101	50524454
Cancer pain	21.49	13.90	18	44551	2569	50557986
Suicidal ideation	21.41	13.90	11	44558	55374	50505181
Adverse event	21.40	13.90	6	44563	43757	50516798
Urticaria	21.28	13.90	52	44517	129509	50431046
Cardiac failure	21.28	13.90	127	44442	75913	50484642
Neoplasm malignant	21.13	13.90	57	44512	23658	50536897
Osteopenia	20.58	13.90	46	44523	16972	50543583
Actinomycosis	20.58	13.90	12	44557	957	50559598
Blood glucose increased	20.53	13.90	120	44449	71204	50489351
Periodontal disease	20.29	13.90	14	44555	1496	50559059
Cell marker increased	20.28	13.90	8	44561	265	50560290
Concomitant disease aggravated	20.26	13.90	30	44539	8061	50552494
Hepatic function abnormal	20.13	13.90	69	44500	32612	50527943
Radiation fibrosis	19.94	13.90	5	44564	34	50560521
Skin lesion	19.70	13.90	60	44509	26667	50533888
Leukopenia	19.68	13.90	114	44455	67414	50493141
Coma	19.57	13.90	13	44556	56866	50503689
Drug interaction	19.45	13.90	100	44469	199521	50361034
Acne	19.40	13.90	49	44520	19546	50541009
Contusion	19.24	13.90	44	44525	112139	50448416
Radioisotope scan	19.14	13.90	4	44565	10	50560545
Ocular vasculitis	19.12	13.90	5	44564	41	50560514
Cardio-respiratory arrest	18.98	13.90	12	44557	53880	50506675
Suicide attempt	18.94	13.90	11	44558	51721	50508834
Fibromyalgia	18.83	13.90	8	44561	44970	50515585
Diarrhoea	18.79	13.90	663	43906	587813	49972742
Onychoclasis	18.72	13.90	23	44546	5173	50555382
Psoriasis	18.56	13.90	20	44549	68980	50491575
Recurrent cancer	18.38	13.90	14	44555	1743	50558812
Carcinoembryonic antigen increased	18.25	13.90	13	44556	1461	50559094
Lung disorder	18.20	13.90	83	44486	44716	50515839
Thrombocytopenia	18.14	13.90	182	44387	127491	50433064
Oral disorder	18.10	13.90	28	44541	7816	50552739
Folliculitis	18.05	13.90	6	44563	39219	50521336
Unevaluable event	18.03	13.90	9	44560	46057	50514498
Product use in unapproved indication	17.85	13.90	48	44521	115771	50444784
Heart rate decreased	17.85	13.90	5	44564	36492	50524063
Arthralgia	17.85	13.90	509	44060	438193	50122362
Bone debridement	17.71	13.90	7	44562	233	50560322
Congestive cardiomyopathy	17.62	13.90	23	44546	5495	50555060
Sedation	17.38	13.90	3	44566	30607	50529948
Lacrimation increased	17.36	13.90	43	44526	16949	50543606
Peripheral sensory neuropathy	17.31	13.90	25	44544	6566	50553989
Hip arthroplasty	17.24	13.90	3	44566	30426	50530129
Hilar lymphadenopathy	17.19	13.90	11	44558	1036	50559519
Fibrin D dimer increased	17.18	13.90	20	44549	4252	50556303
Biopsy site unspecified abnormal	17.16	13.90	4	44565	19	50560536
Heart rate increased	17.05	13.90	26	44543	77224	50483331
Loss of consciousness	17.04	13.90	42	44527	104311	50456244
Lymphangitis	17.00	13.90	10	44559	810	50559745
Lymphatic obstruction	16.99	13.90	4	44565	20	50560535
Bone neoplasm	16.98	13.90	9	44560	596	50559959
Bronchitis	16.95	13.90	42	44527	104117	50456438
Abscess jaw	16.87	13.90	12	44557	1346	50559209
Neoplasm recurrence	16.68	13.90	15	44554	2354	50558201
Cell-mediated immune deficiency	16.68	13.90	4	44565	22	50560533
Dermatitis	16.65	13.90	38	44531	14213	50546342
Metastases to bone marrow	16.57	13.90	7	44562	277	50560278
Hiccups	16.34	13.90	13	44556	1726	50558829
Gastrointestinal disorder	16.24	13.90	37	44532	94419	50466136
Breast pain	16.12	13.90	26	44543	7518	50553037
Bone marrow tumour cell infiltration	16.11	13.90	4	44565	26	50560529
Pleural mass	16.03	13.90	3	44566	3	50560552
Pustule	16.01	13.90	11	44558	1167	50559388
Metastases to bladder	15.99	13.90	6	44563	173	50560382
Fractured sacrum	15.95	13.90	13	44556	1785	50558770
Wound treatment	15.93	13.90	6	44563	175	50560380
Nasopharyngitis	15.91	13.90	102	44467	192825	50367730
Fingerprint loss	15.85	13.90	4	44565	28	50560527
Blood phosphorus decreased	15.68	13.90	18	44551	3771	50556784
Exostosis of jaw	15.67	13.90	11	44558	1208	50559347
Blood pressure fluctuation	15.60	13.90	6	44563	35817	50524738
Fluid retention	15.59	13.90	13	44556	50636	50509919
Pneumonitis chemical	15.55	13.90	6	44563	187	50560368
Drug intolerance	15.55	13.90	121	44448	218983	50341572
Metastases to abdominal wall	15.48	13.90	5	44564	91	50560464
Dry skin	15.36	13.90	77	44492	43114	50517441
Blood pressure decreased	15.27	13.90	16	44553	55893	50504662
Metastases to ovary	15.17	13.90	7	44562	343	50560212
Alanine aminotransferase increased	15.08	13.90	131	44438	88228	50472327
Congenital haematological disorder	15.07	13.90	4	44565	35	50560520
Aortic arteriosclerosis	15.00	13.90	21	44548	5361	50555194
Respiratory arrest	14.88	13.90	4	44565	30005	50530550
Nail infection	14.86	13.90	13	44556	1968	50558587
Recall phenomenon	14.84	13.90	8	44561	548	50560007
Corneal epithelial microcysts	14.82	13.90	3	44566	6	50560549
Ascariasis	14.82	13.90	3	44566	6	50560549
Radiation pneumonitis	14.77	13.90	11	44558	1324	50559231
Hyperbaric oxygen therapy	14.77	13.90	4	44565	38	50560517
Hyperparathyroidism secondary	14.66	13.90	11	44558	1339	50559216
Computerised tomogram abnormal	14.56	13.90	13	44556	2021	50558534
Red blood cell sedimentation rate increased	14.44	13.90	4	44565	29412	50531143
Alveolar lung disease	14.43	13.90	5	44564	114	50560441
Cardiomyopathy	14.43	13.90	38	44531	15548	50545007
Breast inflammation	14.35	13.90	5	44564	116	50560439
Skin mass	14.26	13.90	20	44549	5115	50555440
Encephalopathy	14.10	13.90	6	44563	33705	50526850
Depressed level of consciousness	14.04	13.90	15	44554	51938	50508617
Rib fracture	14.02	13.90	43	44526	19178	50541377
Metastases to eye	13.92	13.90	5	44564	127	50560428

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Metastases to bone	1005.04	14.46	380	31992	20055	64446305
Malignant neoplasm progression	870.14	14.46	597	31775	112274	64354086
Metastases to liver	652.86	14.46	292	32080	23649	64442711
Neoplasm progression	641.68	14.46	342	32030	40622	64425738
Osteonecrosis of jaw	410.01	14.46	253	32119	39572	64426788
Disease progression	363.69	14.46	400	31972	141280	64325080
Metastases to lung	328.19	14.46	158	32214	15106	64451254
Stomatitis	308.44	14.46	325	32047	109280	64357080
Metastases to lymph nodes	291.95	14.46	123	32249	8594	64457766
Breast cancer metastatic	290.68	14.46	116	32256	7053	64459307
Tumour marker increased	263.48	14.46	89	32283	3361	64462999
Pneumonitis	179.60	14.46	170	32202	50195	64416165
Metastases to skin	174.97	14.46	53	32319	1399	64464961
Mucosal inflammation	166.00	14.46	180	32192	62404	64403956
Breast cancer	162.29	14.46	127	32245	29021	64437339
Drug ineffective	130.82	14.46	138	32234	840109	63626251
Bone pain	129.94	14.46	139	32233	47433	64418927
Pleural effusion	126.04	14.46	227	32145	126332	64340028
Osteonecrosis	125.67	14.46	108	32264	28121	64438239
PIK3CA-activated mutation	121.86	14.46	32	32340	493	64465867
Nail disorder	120.94	14.46	67	32305	8557	64457803
Lymphoedema	114.91	14.46	68	32304	9837	64456523
Hot flush	108.86	14.46	125	32247	46110	64420250
Carbohydrate antigen 15-3 increased	97.74	14.46	31	32341	956	64465404
Bone disorder	97.57	14.46	75	32297	16684	64449676
Pseudocirrhosis	97.22	14.46	28	32344	617	64465743
Breast cancer recurrent	95.07	14.46	39	32333	2544	64463816
Pleural neoplasm	87.60	14.46	21	32351	218	64466142
Bone lesion	86.29	14.46	45	32327	5092	64461268
Fatigue	84.25	14.46	652	31720	748078	63718282
Metastases to pleura	82.50	14.46	29	32343	1235	64465125
Exposed bone in jaw	80.73	14.46	38	32334	3449	64462911
Cough	78.73	14.46	330	32042	301818	64164542
Ejection fraction decreased	78.58	14.46	84	32288	28623	64437737
Hypotension	77.19	14.46	48	32324	380926	64085434
Metastases to spine	73.13	14.46	36	32336	3607	64462753
Metastases to central nervous system	71.81	14.46	58	32314	13854	64452506
Hepatic lesion	67.59	14.46	40	32332	5784	64460576
Second primary malignancy	67.02	14.46	53	32319	12284	64454076
Off label use	65.08	14.46	138	32234	632668	63833692
Neuropathy peripheral	60.82	14.46	162	32210	117363	64348997
Metastases to peritoneum	59.37	14.46	31	32341	3516	64462844
Device related thrombosis	58.59	14.46	26	32346	2059	64464301
Hormone receptor positive breast cancer	57.89	14.46	16	32356	302	64466058
Tooth extraction	55.96	14.46	43	32329	9558	64456802
Toxicity to various agents	55.95	14.46	60	32312	363453	64102907
Aphthous ulcer	54.64	14.46	48	32324	12858	64453502
Drug abuse	54.21	14.46	3	32369	132371	64333989
Malignant pleural effusion	52.74	14.46	27	32345	2940	64463420
Lymphangiosis carcinomatosa	52.11	14.46	23	32349	1798	64464562
Lymphadenopathy mediastinal	51.31	14.46	29	32343	3847	64462513
Neutropenia	51.28	14.46	247	32125	239377	64226983
Oral pain	51.14	14.46	66	32306	27427	64438933
Ascites	50.29	14.46	102	32270	61899	64404461
Osteolysis	48.35	14.46	25	32347	2778	64463582
Rheumatoid arthritis	47.41	14.46	12	32360	164282	64302078
Peritoneal disorder	46.64	14.46	16	32356	633	64465727
Overdose	45.38	14.46	12	32360	159554	64306806
Bone sequestrum	44.17	14.46	18	32354	1154	64465206
Metastasis	43.40	14.46	30	32342	5665	64460695
Therapeutic product effect decreased	43.25	14.46	4	32368	115347	64351013
Interstitial lung disease	42.96	14.46	127	32245	97605	64368755
Metastases to the mediastinum	41.65	14.46	14	32358	520	64465840
Acute kidney injury	39.69	14.46	106	32266	449134	64017226
Bradycardia	39.63	14.46	6	32366	118213	64348147
Arthralgia	38.82	14.46	365	32007	441895	64024465
Palmar-plantar erythrodysaesthesia syndrome	38.44	14.46	59	32313	28760	64437600
Oral cavity fistula	38.42	14.46	14	32358	662	64465698
Abdominal lymphadenopathy	38.06	14.46	16	32356	1110	64465250
Creutzfeldt-Jakob disease	37.05	14.46	10	32362	172	64466188
Decreased appetite	36.55	14.46	254	32118	281035	64185325
Dysgeusia	36.50	14.46	76	32296	46971	64419389
Superinfection	35.71	14.46	23	32349	3863	64462497
Infusion related reaction	35.70	14.46	19	32353	164448	64301912
Asthenia	34.48	14.46	347	32025	427697	64038663
Injection site pain	34.41	14.46	7	32365	111401	64354959
Intentional overdose	34.04	14.46	3	32369	89941	64376419
Metastases to soft tissue	33.46	14.46	11	32361	381	64465979
Trigger finger	32.62	14.46	21	32351	3524	64462836
Invasive ductal breast carcinoma	32.53	14.46	24	32348	5018	64461342
Sequestrectomy	31.86	14.46	13	32359	836	64465524
Hyperglycaemia	31.47	14.46	84	32288	60884	64405476
Weight decreased	31.41	14.46	248	32124	285491	64180869
Synovitis	31.07	14.46	6	32366	99084	64367276
Skin toxicity	30.88	14.46	26	32346	6576	64459784
Gingival swelling	30.70	14.46	21	32351	3899	64462461
Metastases to eye	30.48	14.46	9	32363	217	64466143
Joint swelling	30.45	14.46	38	32334	215344	64251016
Fibrous histiocytoma	30.03	14.46	11	32361	528	64465832
Metastases to chest wall	29.51	14.46	10	32362	381	64465979
Myocardial infarction	29.44	14.46	24	32348	165797	64300563
Nail dystrophy	28.99	14.46	12	32360	801	64465559
Pathological fracture	27.59	14.46	28	32344	8977	64457383
Drug interaction	27.23	14.46	92	32280	361991	64104369
Mouth ulceration	27.04	14.46	54	32318	32390	64433970
Tumour marker abnormal	27.01	14.46	8	32364	195	64466165
Lacrimation increased	26.52	14.46	39	32333	18307	64448053
Pulmonary mass	26.35	14.46	45	32327	23971	64442389
Fall	26.14	14.46	114	32258	416712	64049648
Mouth swelling	25.74	14.46	21	32351	5086	64461274
Intentional product use issue	25.58	14.46	8	32364	95356	64371004
Osteitis	25.09	14.46	18	32354	3604	64462756
Cardio-respiratory arrest	25.09	14.46	9	32363	98384	64367976
Pain in jaw	25.05	14.46	60	32312	40695	64425665
Confusional state	24.26	14.46	60	32312	261084	64205276
Radioisotope scan	24.15	14.46	4	32368	3	64466357
Alopecia	24.13	14.46	154	32218	165536	64300824
Lung disorder	23.97	14.46	76	32296	60624	64405736
Hallucination	23.70	14.46	4	32368	72784	64393576
Pulmonary tumour thrombotic microangiopathy	23.38	14.46	6	32366	84	64466276
Axillary pain	23.04	14.46	13	32359	1719	64464641
Pancreatic neoplasm	22.80	14.46	12	32360	1383	64464977
Radiation fibrosis	22.37	14.46	5	32367	37	64466323
Oral herpes	22.34	14.46	40	32332	22112	64444248
Nail infection	22.26	14.46	13	32359	1834	64464526
General physical health deterioration	22.21	14.46	177	32195	204248	64262112
Osteomyelitis	21.90	14.46	45	32327	27542	64438818
Diarrhoea	21.90	14.46	495	31877	722209	63744151
Metastases to meninges	21.85	14.46	15	32357	2800	64463560
Blood alkaline phosphatase increased	21.80	14.46	70	32302	56209	64410151
Cell marker increased	21.29	14.46	9	32363	633	64465727
Hepatic atrophy	21.27	14.46	8	32364	414	64465946
Debridement	21.08	14.46	12	32360	1614	64464746
Breast mass	20.99	14.46	19	32353	5291	64461069
Therapeutic product effect incomplete	20.96	14.46	13	32359	103469	64362891
Rhabdomyolysis	20.79	14.46	10	32362	91716	64374644
Pustule	20.22	14.46	11	32361	1354	64465006
Epistaxis	20.11	14.46	100	32272	98031	64368329
Breast cancer female	19.66	14.46	18	32354	5085	64461275
Fractured sacrum	19.43	14.46	11	32361	1464	64464896
Treatment failure	19.40	14.46	18	32354	116798	64349562
Carcinoid tumour pulmonary	19.31	14.46	7	32365	326	64466034
Nipple exudate bloody	19.29	14.46	5	32367	73	64466287
Metastases to thorax	19.23	14.46	6	32366	175	64466185
Vaginal discharge	19.23	14.46	16	32356	3981	64462379
Coma	19.18	14.46	10	32362	87605	64378755
Nausea	18.97	14.46	522	31850	785278	63681082
Injection site erythema	18.88	14.46	6	32366	70794	64395566
Periodontitis	18.68	14.46	16	32356	4143	64462217
White blood cell count decreased	18.43	14.46	139	32233	157698	64308662
Periodontal disease	18.03	14.46	11	32361	1680	64464680
Somnolence	17.98	14.46	48	32324	203597	64262763
Mucosal ulceration	17.82	14.46	11	32361	1716	64464644
Progesterone receptor assay positive	17.64	14.46	6	32366	231	64466129
Bone neoplasm	17.36	14.46	8	32364	692	64465668
Congenital haematological disorder	17.30	14.46	4	32368	35	64466325
Loss of consciousness	17.22	14.46	30	32342	148335	64318025
Cardiac arrest	17.12	14.46	32	32340	154032	64312328
Teeth brittle	17.03	14.46	7	32365	459	64465901
Recurrent cancer	16.91	14.46	12	32360	2361	64463999
Gingivitis	16.83	14.46	20	32352	7639	64458721
Haematotoxicity	16.63	14.46	26	32346	12870	64453490
Dry skin	16.62	14.46	60	32312	51101	64415259
Feeding disorder	16.55	14.46	26	32346	12923	64453437
Ascariasis	16.50	14.46	3	32369	6	64466354
Back pain	16.48	14.46	195	32177	249976	64216384
Incorrect dose administered	16.47	14.46	5	32367	60760	64405600
Breast pain	16.45	14.46	19	32353	7042	64459318
Tremor	16.29	14.46	31	32341	148199	64318161
Lymphadenopathy	16.24	14.46	56	32316	46630	64419730
Tumour marker decreased	16.16	14.46	4	32368	48	64466312
Metastases to pelvis	16.06	14.46	7	32365	531	64465829
Exostosis of jaw	15.98	14.46	9	32363	1185	64465175
Heart rate decreased	15.92	14.46	4	32368	55063	64411297
Hydrothorax	15.55	14.46	9	32363	1248	64465112
Arthropathy	15.41	14.46	23	32349	120944	64345416
Pericardial effusion	15.36	14.46	49	32323	39205	64427155
Acne	15.29	14.46	35	32337	23046	64443314
Dyspnoea	15.29	14.46	470	31902	718204	63748156
Actinomycosis	15.10	14.46	8	32364	934	64465426
Sinusitis	14.77	14.46	32	32340	145896	64320464
Skin mass	14.71	14.46	18	32354	7088	64459272
Recall phenomenon	14.61	14.46	8	32364	998	64465362
Carcinoembryonic antigen increased	14.59	14.46	10	32362	1863	64464497
Blood pressure fluctuation	14.55	14.46	4	32368	51867	64414493
Hospitalisation	14.48	14.46	10	32362	75197	64391163

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L02BG06	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY HORMONE ANTAGONISTS AND RELATED AGENTS Aromatase inhibitors
FDA MoA	N0000175080	Aromatase Inhibitors
FDA EPC	N0000175563	Aromatase Inhibitor
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:35703	Xenobiotic
CHEBI has role	CHEBI:50790	aromatase inhibitors
CHEBI has role	CHEBI:78298	environmental contaminants
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D047072	Aromatase Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D004965	Estrogen Antagonists
MeSH PA	D006727	Hormone Antagonists
MeSH PA	D065088	Steroid Synthesis Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hormone receptor positive malignant neoplasm of breast	indication	417181009
Advanced Breast Cancer Progression Post-Antiestrogen Therapy	indication
Prevention of Breast Carcinoma	off-label use
Pregnancy, function	contraindication	289908002
Osteopenia	contraindication	312894000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Aromatase	Enzyme	P11511	CP19A_HUMAN	INHIBITOR	IC50	5.69		WOMBAT-PK	CHEMBL
Androgen receptor	Nuclear hormone receptor	P10275	ANDR_HUMAN					WOMBAT-PK

External reference:

ID	Source
4021191	VUID
N0000148637	NUI
D00963	KEGG_DRUG
4021191	VANDF
C0851344	UMLSCUI
CHEBI:4953	CHEBI
EXM	PDB_CHEM_ID
CHEMBL1200374	ChEMBL_ID
DB00990	DRUGBANK_ID
C056516	MESH_SUPPLEMENTAL_RECORD_UI
60198	PUBCHEM_CID
7073	IUPHAR_LIGAND_ID
6770	INN_ID
NY22HMQ4BX	UNII
258494	RXNORM
180650	MMSL
31449	MMSL
8478	MMSL
d04461	MMSL
007997	NDDF
116115004	SNOMEDCT_US
387017005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Aromasin	HUMAN PRESCRIPTION DRUG LABEL	1	0009-7663	TABLET	25 mg	ORAL	NDA	27 sections
Exemestane	HUMAN PRESCRIPTION DRUG LABEL	1	0054-0080	TABLET, FILM COATED	25 mg	ORAL	ANDA	27 sections
Exemestane	HUMAN PRESCRIPTION DRUG LABEL	1	0378-5001	TABLET, FILM COATED	25 mg	ORAL	ANDA	27 sections
Exemestane	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0595	TABLET	25 mg	ORAL	ANDA	27 sections
Exemestane	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0595	TABLET	25 mg	ORAL	ANDA	27 sections
Exemestane	HUMAN PRESCRIPTION DRUG LABEL	1	44278-025	TABLET	25 mg	ORAL	ANDA	26 sections
Exemestane	HUMAN PRESCRIPTION DRUG LABEL	1	47781-108	TABLET	25 mg	ORAL	ANDA	26 sections
Exemestane	HUMAN PRESCRIPTION DRUG LABEL	1	50090-5193	TABLET	25 mg	ORAL	ANDA	26 sections
Exemestane	HUMAN PRESCRIPTION DRUG LABEL	1	51991-005	TABLET, FILM COATED	25 mg	ORAL	ANDA	31 sections
Aromasin	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5261	TABLET	25 mg	ORAL	NDA	13 sections
Exemestane	Human Prescription Drug Label	1	59651-516	TABLET, FILM COATED	25 mg	ORAL	ANDA	26 sections
EXEMESTANE	HUMAN PRESCRIPTION DRUG LABEL	1	59762-2858	TABLET, SUGAR COATED	25 mg	ORAL	NDA AUTHORIZED GENERIC	28 sections
Exemestane	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2056	TABLET, FILM COATED	25 mg	ORAL	ANDA	30 sections
Exemestane	HUMAN PRESCRIPTION DRUG LABEL	1	63629-2056	TABLET, FILM COATED	25 mg	ORAL	ANDA	30 sections
Exemestane	HUMAN PRESCRIPTION DRUG LABEL	1	65162-240	TABLET, FILM COATED	25 mg	ORAL	ANDA	25 sections
Exemestane	HUMAN PRESCRIPTION DRUG LABEL	1	65162-240	TABLET, FILM COATED	25 mg	ORAL	ANDA	25 sections
Exemestane	HUMAN PRESCRIPTION DRUG LABEL	1	68382-383	TABLET	25 mg	ORAL	ANDA	25 sections
EXEMESTANE	HUMAN PRESCRIPTION DRUG LABEL	1	69097-316	TABLET	25 mg	ORAL	ANDA	22 sections
Exemestane	HUMAN PRESCRIPTION DRUG LABEL	1	70771-1374	TABLET	25 mg	ORAL	ANDA	1 sections
Exemestane	HUMAN PRESCRIPTION DRUG LABEL	1	71921-190	TABLET, FILM COATED	25 mg	ORAL	ANDA	28 sections
Exemestane	HUMAN PRESCRIPTION DRUG LABEL	1	71921-190	TABLET, FILM COATED	25 mg	ORAL	ANDA	28 sections